Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Myelodysplastic syndromes / neoplasms (MDS), drawn from the whole corpus: 70 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
9 medicines on record are linked to one of the types below rather than to Myelodysplastic syndromes / neoplasms (MDS) itself. Grouped by the type that holds them; each list opens that type's own page.
No drug has beaten azacitidine in higher-risk MDS.
TP53-mutant and complex-karyotype disease: median survival about a year even after transplant.
Clonal cytopenia of undetermined significance (CCUS): who to watch, who to treat.
Post-HMA failure has no standard.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 36 changes by month →When this page itself was last checked or edited.
FDA approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Lower-risk MDS transfusion-dependent anaemia
Preparative regimen for allogeneic HSCT in AML/MDS with fludarabine
Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes.
FDA approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs).